Vol 6, No 4 (2017)
Review article
Published online: 2017-11-17
The impact of dapagliflozin on cardiovascular system in the course of type 2 diabetes mellitus
DOI: 10.5603/DK.2017.0024
Clin Diabetol 2017;6(4):142-146.
Abstract
The following paper is an attempt to revise current data and the results of clinical trials concerning the impact of dapagliflozin on long-term cardiovascular complications of type 2 diabetes mellitus. Short-term clinical trials, including relatively small groups of patients, suggest positive influence of dapagliflozin on the cardiovascular system. Currently ongoing long-term trials are likely to confirm these data, but so far we can assume that dapagliflozin not only acts as an efficient antihyperglycaemic drug, but also protects the circulatory system in patients with type 2 diabetes mellitus.
Keywords: dapagliflozinrisk factorscardiovascular eventsatherosclerosis
References
- Stamler J, Vaccaro O, Neaton JD, et al. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care. 1993; 16(2): 434–444.
- Ferrannini E, DeFronzo RA. Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes. Eur Heart J. 2015; 36(34): 2288–2296.
- Charakterystyka produktu leczniczego Forxiga 5 mg, 10 mg 2017.
- Scheen AJ. Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus. Drugs. 2015; 75(1): 33–59.
- Birkeland KI, Jørgensen ME, Carstensen B, et al. Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis. Lancet Diabetes Endocrinol. 2017; 2(17): 1–9.
- Liakos A, Karagiannis T, Bekiari E, et al. Update on long-term efficacy and safety of dapagliflozin in patients with type 2 diabetes mellitus. Ther Adv Endocrinol Metab. 2015; 6(2): 61–67.
- Bolinder J, Ljunggren Ö, Kullberg J, et al. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J Clin Endocrinol Metab. 2012; 97(3): 1020–1031.
- Halimi S, Vergès B. Adverse effects and safety of SGLT-2 inhibitors. Diabetes Metab. 2014; 40(6 Suppl 1): S28–S34.
- Singh JSS, Fathi A, Vickneson K, et al. Research into the effect Of SGLT2 inhibition on left ventricular remodelling in patients with heart failure and diabetes mellitus (REFORM) trial rationale and design. Cardiovasc Diabetol. 2016; 15: 97.
- González-Ortiz M, Méndez-Del Vi, Martínez-Abundis E, et al. Effect of dapagliflozin administration on metabolic syndrome, insulin sensitivity, and insulin secretion. Minerva Endocrinol. ; 2016: 2016.
- Bailey CJ, Gross JL, Hennicken D, et al. Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial. BMC Med. 2013; 11: 43.
- Cefalu WT, Leiter LA, de Bruin TWA, et al. Dapagliflozin's Effects on Glycemia and Cardiovascular Risk Factors in High-Risk Patients With Type 2 Diabetes: A 24-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With a 28-Week Extension. Diabetes Care. 2015; 38(7): 1218–1227.
- Strojek K, Yoon KH, Hruba V, et al. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial. Diabetes Obes Metab. 2011; 13(10): 928–938.
- Bolinder J, Ljunggren Ö, Johansson L, et al. Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin. Diabetes Obes Metab. 2014; 16(2): 159–169.
- Nalysnyk L, Hernandez-Medina M, Krishnarajah G. Glycaemic variability and complications in patients with diabetes mellitus: evidence from a systematic review of the literature. Diabetes Obes Metab. 2010; 12(4): 288–298.
- Suh S, Kim JH. Glycemic Variability: How Do We Measure It and Why Is It Important? Diabetes Metab J. 2015; 39(4): 273–282.
- Li FF, Gao Gu, Li Q, et al. Influence of Dapagliflozin on Glycemic Variations in Patients with Newly Diagnosed Type 2 Diabetes Mellitus. J Diabetes Res. 2016; 2016: 5347262.
- ClinicalTrials.gov. Effect of Dapagliflozin on 24-hour Blood Glucose in T2DM Patients Inadequately Controlled With Either Metformin Or Insulin - Study Results. https://clinicaltrials.gov/ct2/show/results/NCT02429258 (2017).
- Mudaliar S, Henry RR, Boden G, et al. Changes in insulin sensitivity and insulin secretion with the sodium glucose cotransporter 2 inhibitor dapagliflozin. Diabetes Technol Ther. 2014; 16(3): 137–144.
- Heerspink HJL, Johnsson E, Gause-Nilsson I, et al. Dapagliflozin reduces albuminuria in patients with diabetes and hypertension receiving renin-angiotensin blockers. Diabetes Obes Metab. 2016; 18(6): 590–597.
- European Medicines Agency. Assessment report - Forxiga. 2012.
- Sonesson C, Johansson PA, Johnsson E, et al. Cardiovascular effects of dapagliflozin in patients with type 2 diabetes and different risk categories: a meta-analysis. Cardiovasc Diabetol. 2016; 15: 37.
- ClinicalTrials.gov. Multicenter Trial to Evaluate the Effect of Dapagliflozin on the Incidence of Cardiovascular Events - Full Text View - ClinicalTrials.gov [Internet]. 2017. p. 6–8. https://www.clinicaltrials.gov/ct2/show/NCT01730534 (2017).